Trestolone acetate

Trestolone acetate (USAN; developmental code names CDB-903, NSC-69948, U-15614; also known as 7α-methyl-19-nortestosterone 17β-acetate (MENT acetate) and 7α-methylestr-4-en-17β-ol-3-one 17β-acetate) is a synthetic and injected anabolic–androgenic steroid (AAS) and a derivative of nandrolone (19-nortestosterone) which was never marketed.[1] It is an androgen ester – specifically, the C17 acetate ester of trestolone (7α-methyl-19-nortestosterone; MENT).[1] The medication was first described in 1963.[2]

Trestolone acetate
Clinical data
Other namesOrgasteron acetate; MENT acetate; CDB-903; NSC-69948; U-15614; 7α-Methyl-19-nortestosterone 17β-acetate; 7α-Methylestr-4-en-17β-ol-3-one 17β-acetate
Routes of
administration		Intramuscular injection
Drug classAndrogen; Anabolic steroid; Androgen ester; Progestogen; Antigonadotropin
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H30O3
Molar mass330.468 g·mol−1
3D model (JSmol)

See also

References
  1. Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 888–. ISBN 978-1-4757-2085-3.
  2. Campbell JA, Lyster SC, Duncan GW, Babcock JC (1963). "7α-Methyl-18-norsteroids: A new class of potent anabolic and androgenic hormones". Steroids. 1 (3): 317–324. doi:10.1016/S0039-128X(63)80114-2.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.